证券代码：600107 证券简称：美尔雅 公告编号：2025026 湖北美尔雅股份有限公司 关于提供反担保暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、反担保情况概述 （一）本次反担保的基本情况 湖北美尔雅股份有限公司（以下简称"公司"）根据经营业务发展需要，兴 业银行黄石分行、黄石农商行分别为公司提供了 1 亿元、5,000 万元的流动资金 贷款，黄石众盛科技有限公司（以下简称"众盛公司"）以其房屋为上述贷款提 供抵押担保，所承担的担保责任为最高本金限额合计 23,163.7 万元，其中与兴 业银行黄石分行签订了《最高额抵押合同》，抵押最高本金限额为 12,463.7 万元； 与黄石农商行签订了《最高额抵押合同》，抵押最高本金限额为 10,700 万元。为 保障众盛公司自身权益，公司以持有的湖北美尔雅销售有限公司（以下简称"销 售公司"）95.6022%股权和对销售公司享有的 15,555.36 万元债权为众盛公司提 供质押担保。 二、被担保人的情况 （一）被担保人的基本情况 公司名称 ...

湖北美尔雅股份有限公司 关于会计师事务所 2024 年度履职情况的评估报告 经湖北美尔雅股份有限公司（以下简称"公司"）股东大会批准，公司聘请 中审众环会计师事务所（特殊普通合伙）（以下简称"中审众环"）作为公司 2024 年度财务审计及内部控制审计机构。根据财政部、国资委及证监会颁布的《国有 企业、上市公司选聘会计师事务所管理办法》，公司对中审众环 2024 年度审计过 程中的履职情况进行了评估。经评估，公司认为，中审众环在资质条件等方面合 规有效，能够保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、会计师事务所的基本情况 中审众环始创于 1987 年，是全国首批取得国家批准具有从事证券、期货相 关业务资格及金融业务审计资格的大型会计师事务所之一。根据财政部、证监会 发布的从事证券服务业务会计师事务所备案名单，中审众环具备股份有限公司发 行股份、债券审计机构的资格。2013 年 11 月，按照国家财政部等有关要求转制 为特殊普通合伙制。 中审众环首席合伙人为石文先，注册地址为湖北省武汉市武昌区水果湖街道 中北路 166 号长江产业大厦 17-18 楼，组织形式为特殊普通合伙。截至 2024 年 末合 ...

公司监事会认为：上述审计意见在所有重大方面真实、准确、公允地反映了 公司 2024 年度财务状况和经营成果。监事会同意《湖北美尔雅股份有限公司董 事会关于 2024 年度非标准内部控制审计报告涉及事项的专项说明》，将持续关 注、监督公司董事会和管理层相关工作的开展情况，督促公司董事会和管理层采 取有效措施消除涉及事项的影响，切实维护广大投资者利益。 湖北美尔雅股份有限公司 监事会对董事会关于2024年度非标准内部控制审计报告 涉及事项的专项说明的意见 湖北美尔雅股份有限公司（以下简称"公司"）聘请的中审众环会计师事务 所（特殊普通合伙）为公司 2024 年度内部控制审计报告出具了否定意见的审计 报告。公司董事会出具了《湖北美尔雅股份有限公司董事会关于 2024 年度非标 准内部控制审计报告涉及事项的专项说明》。根据中国证券监督管理委员会《公 开发行证券的公司信息披露内容与格式准则第 2 号——年度报告的内容与格 式》、《公开发行证券的公司信息披露编报规则第 14 号——非标准无保留审计 意见涉及事项的处理》及《上海证券交易所股票上市规则》等相关规定，监事会 对《湖北美尔雅股份有限公司董事会关于 2024 年度 ...

证券代码：600107 证券简称：美尔雅 公告编号：2025017 （三）监事出席会议情况及列席人员 本次会议应出席监事4人，实际出席4人，公司部分高级管理人员列席了会议。 湖北美尔雅股份有限公司 第十二届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）会议通知时间、方式 湖北美尔雅股份有限公司（以下简称"公司"）第十二届监事会第十二次会议通 知于2025年4月18日以传真、邮件、电话等形式发出。 （二）会议召开时间、地点、方式 本次会议于2025年4月28日在公司会议室采取现场结合通讯方式召开。 （四）会议主持人 本次会议由监事会主席郑鹏飞先生主持。 （五）会议召开的合规性 本次会议的召集、召开程序符合《中华人民共和国公司法》、《公司章程》及有 关法律、行政法规、部门规章、规范性文件的规定。 二、议案审议情况 本次会议议案采用书面记名投票表决方式进行，会议对以下议案进行了审议： (一) 《2024 年度监事会工作报告》 具体内容详见公司同日于上海证券交易所网站（htt ...

湖北美尔雅股份有限公司 公司监事会认为：上述审计意见在所有重大方面真实、准确、公允地反映了 公司 2024 年度财务状况和经营成果，监事会同意《湖北美尔雅股份有限公司董 事会关于非标准审计意见涉及事项的专项说明》，将持续关注、监督公司董事会 和管理层相关工作的开展情况，督促公司董事会和管理层采取有效措施消除审计 报告中保留意见涉及事项的影响，切实维护广大投资者利益。 2025 年 4 月 30 日 专项说明的意见 湖北美尔雅股份有限公司（以下简称"公司"）聘请的中审众环会计师事务 所（特殊普通合伙）为公司 2024 年度财务报告出具了保留意见的审计报告。公 司董事会出具了《湖北美尔雅股份有限公司董事会关于非标准审计意见涉及事项 的专项说明》。根据中国证券监督管理委员会《公开发行证券的公司信息披露内 容与格式准则第 2 号——年度报告的内容与格式》、《公开发行证券的公司信息 披露编报规则第 14 号——非标准无保留审计意见涉及事项的处理》及《上海证 券交易所股票上市规则》等相关规定，监事会对《湖北美尔雅股份有限公司董事 会关于非标准审计意见涉及事项的专项说明》进行了认真审核，并提出如下书面 审核意见： 湖北美尔 ...

Financial Performance - The company's operating revenue for the third quarter was ¥52,684,422.78, a decrease of 48.23% compared to the same period last year[4] - The net profit attributable to shareholders was -¥21,074,438.64, representing a decline of 484.95% year-on-year[4] - The basic earnings per share for the third quarter was -¥0.06, a decrease of 400.00% compared to the previous year[4] - Total operating revenue for the first three quarters of 2024 was CNY 257,421,589.13, a decrease of 20.1% compared to CNY 322,022,176.36 in the same period of 2023[19] - Net profit for the first three quarters of 2024 was a loss of CNY 48,992,214.79, compared to a loss of CNY 10,800,034.96 in the same period of 2023[20] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥61,606,335.50, compared to -¥120,016,302.55 in the same period last year[4] - The net cash flow from operating activities was negative CNY 61,606,335.50, slightly worse than the negative CNY 58,016,302.55 in the previous year[23] - Cash inflow from investment activities totaled CNY 268,859,881.60, while cash outflow was CNY 277,637,154.35, resulting in a net cash flow of negative CNY 8,777,272.75[23] - The net increase in cash and cash equivalents was -$107.38 million, compared to -$70.90 million previously, reflecting a worsening liquidity position[25] - The ending balance of cash and cash equivalents was $58.99 million, significantly lower than $130.78 million at the end of the previous period[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥878,906,337.38, a decrease of 16.36% from the end of the previous year[5] - The total current assets decreased from ¥876,963,879.46 to ¥686,391,031.73, a reduction of about 21.7%[16] - The total liabilities decreased from ¥458,783,954.64 to ¥337,264,202.56, a decline of approximately 26.5%[17] - The company's total equity attributable to shareholders decreased to CNY 511,738,752.11 from CNY 560,294,829.01[18] - The total liabilities and equity amounted to CNY 878,906,337.38, down from CNY 1,050,792,762.15 in the previous year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,315[12] - Hubei Meierya Group Co., Ltd. holds 20.39% of shares, totaling 73,388,738 shares[12] Operational Challenges - The company reported a significant decline in revenue due to the disposal of equity in Qinghai Zhongyou Health Huijia Pharmaceutical Co., Ltd., which affected the consolidation scope[9] - The decrease in net profit was attributed to reduced export orders in the apparel segment and losses from coal trading due to unreceived subsidies[9] - The company is currently facing challenges in its apparel business due to reduced export orders and is adjusting its strategies accordingly[10] Other Financial Metrics - Non-recurring gains and losses included a government subsidy of ¥339,708.00 and a fair value change of financial assets resulting in a gain of ¥686,519.51[7] - The company's cash and cash equivalents decreased from ¥173,464,257.41 to ¥60,427,222.56, a decline of approximately 65.2%[15] - The company's inventory decreased from ¥255,190,556.44 to ¥219,671,468.97, a reduction of about 13.9%[16] - The company's accounts receivable decreased from ¥50,454,073.11 to ¥40,679,336.38, a decline of approximately 19.4%[15] - The total non-current assets increased from ¥173,828,882.69 to ¥192,515,305.65, an increase of about 10.7%[16] - Total operating costs decreased to CNY 298,124,273.75, down 14.6% from CNY 348,937,270.29 year-over-year[19] - Interest expenses decreased to CNY 6,679,745.25 from CNY 9,985,042.67 year-over-year, reflecting a reduction in financial costs[20]

Financial Performance - The company's operating revenue for Q1 2025 was ¥74,230,286.84, a decrease of 42.78% compared to ¥129,720,721.33 in the same period last year[4] - The net loss attributable to shareholders was ¥8,266,706.90, an improvement from a loss of ¥13,551,576.48 in the previous year[4] - The net profit for Q1 2025 was a loss of ¥8,227,417.20, an improvement from a loss of ¥13,434,310.80 in Q1 2024[19] - The basic and diluted earnings per share were both -¥0.02, unchanged from the previous year[4] - Basic earnings per share for Q1 2025 was -¥0.02, an improvement from -¥0.04 in Q1 2024[20] Cash Flow - The net cash flow from operating activities was ¥12,718,997.17, a significant recovery from a negative cash flow of ¥43,881,042.33 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was ¥12,718,997.17, compared to a negative cash flow of ¥43,881,042.33 in Q1 2024[24] - The company reported a cash flow net increase of negative CNY 31,707,220.25 for the period, compared to negative CNY 38,627,084.63 in the previous period, showing an improvement in cash flow management[25] - In Q1 2025, the net cash flow from operating activities was -$70.64 million, an improvement from -$105.17 million in Q1 2024, indicating a 32.8% reduction in cash outflow[33] - Total cash inflow from operating activities in Q1 2025 was $38.78 million, compared to $15.97 million in Q1 2024, representing a 142.6% increase[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥845,542,286.98, down 3.61% from ¥877,165,138.16 at the end of the previous year[5] - Current assets totaled CNY 668,432,805.32, down from CNY 690,557,780.73, indicating a decrease of about 3.2%[13] - Total liabilities were CNY 332,911,199.87, down from CNY 356,306,633.85, indicating a decrease of approximately 6.5%[14] - The total assets as of March 31, 2025, were CNY 769,788,888.85, down from CNY 780,967,101.93 as of December 31, 2024, indicating a decrease of about 1.54%[28] - The total liabilities decreased to CNY 260,303,578.36 from CNY 266,493,488.87, reflecting a reduction of approximately 2.32%[28] Shareholder Information - Shareholders' equity attributable to the company was ¥483,924,527.40, a decrease of 1.68% from ¥492,191,234.30 at the end of the previous year[5] - The total number of ordinary shareholders at the end of the reporting period was 23,671[9] - The company has no significant changes in the shareholding structure among the top ten shareholders[11] - There are no reported changes in the participation of major shareholders in margin trading or securities lending activities[11] Government Support and Cost Management - The company received government subsidies amounting to ¥3,034,354.63, contributing to the reduction in net loss[6] - The company's management expenses for Q1 2025 were CNY 4,100,834.98, significantly lower than CNY 7,156,475.62 in Q1 2024, indicating a reduction of approximately 42.8%[30] - The company incurred $93.71 million in cash payments related to operating activities in Q1 2025, slightly up from $91.45 million in Q1 2024, showing stable operational costs[33] Investment Activities - Cash inflow from investment activities in Q1 2025 was ¥41,918,385.00, down from ¥100,688,552.15 in Q1 2024[24] - Cash outflow from investment activities for Q1 2025 was ¥77,114,400.00, compared to ¥89,349,505.50 in Q1 2024[24] - Cash flow from investing activities in Q1 2025 was -$9.61 million, a significant decrease from $13.00 million in Q1 2024, reflecting a change in investment strategy[33]

Financial Performance - The company's operating revenue for 2024 was CNY 329,501,963.16, a decrease of 27.42% compared to CNY 453,997,393.11 in 2023[20]. - The net profit attributable to shareholders of the listed company was CNY -68,103,594.71, compared to CNY -59,459,182.66 in the previous year[20]. - The total assets decreased by 16.52% to CNY 877,165,138.16 from CNY 1,050,792,762.15 in 2023[21]. - The net assets attributable to shareholders of the listed company decreased by 12.16% to CNY 492,191,234.30 from CNY 560,294,829.01 in 2023[21]. - Basic earnings per share for 2024 is -0.19 yuan, a decrease of 11.76% compared to -0.17 yuan in 2023[22]. - Diluted earnings per share for 2024 is also -0.19 yuan, reflecting the same percentage decrease of 11.76% from 2023[22]. - The weighted average return on equity decreased to -12.94% in 2024 from -10.12% in 2023, a decline of 2.82 percentage points[22]. - The net profit attributable to shareholders for the first quarter of 2024 was -13,551,576.48 yuan, with losses increasing in subsequent quarters to -13,930,061.78 yuan, -21,074,438.64 yuan, and -19,547,517.81 yuan[25]. - The company achieved a total revenue of 329.5 million yuan, a decrease of 27.42% year-on-year[39]. - The net profit attributable to the parent company was -68.1 million yuan, down 14.54% year-on-year[39]. - The clothing business generated revenue of 286.1 million yuan, a decline of 15.21% compared to the previous year[39]. - The company reported a significant reduction in sales expenses due to the disposal of the Qinghai subsidiary, leading to lower personnel costs and rental fees[45]. - The company reported a net loss of CNY 69,748,274.49 for 2024, compared to a net loss of CNY 57,744,728.19 in 2023, indicating a worsening of 20.5%[199]. Cash Flow and Assets - The cash flow from operating activities was CNY -36,687,877.44, an improvement from CNY -46,507,380.62 in the previous year[21]. - The net cash flow from operating activities was -43,881,042.33 yuan in the first quarter, improving to 24,918,458.06 yuan in the fourth quarter[25]. - Cash and cash equivalents at the end of the period were ¥117,489,434.08, a decrease of 32.27% from ¥173,464,257.41 in the previous period[58]. - The company's total assets decreased slightly from CNY 785,653,747.45 in 2023 to CNY 780,967,101.93 in 2024[195]. - Current assets decreased from CNY 876,963,879.46 in 2023 to CNY 690,557,780.73 in 2024, representing a reduction of about 21.2%[189]. - The company's short-term borrowings decreased from CNY 171,450,000.00 in 2023 to CNY 150,000,000.00 in 2024, a reduction of approximately 12.4%[190]. - The company's other receivables increased from CNY 13,401,630.70 in 2023 to CNY 27,988,211.73 in 2024, an increase of about 108.8%[189]. - The company's prepayments increased significantly from CNY 73,695,147.30 in 2023 to CNY 136,061,401.59 in 2024, an increase of approximately 84.5%[189]. Operational Changes and Strategies - The company plans to take effective measures to eliminate the matters related to the qualified opinion as soon as possible[3]. - The company is actively expanding into overseas markets while maintaining its traditional markets in Japan and Southeast Asia[32]. - The company is focusing on enhancing online channel coverage and market share through strategic adjustments and customer-oriented service[33]. - The company plans to leverage new shareholder resources to accelerate business and product upgrades in its pharmacy chain[42]. - The company plans to open 10 new stores in 2024 while closing 26 existing stores, resulting in a net decrease in store count[62]. - The company aims to maintain stable revenue growth and improve profitability, with the overall business goal subject to adjustments based on macroeconomic conditions and market trends[78]. - The company plans to increase its shareholding by no less than RMB 15 million and no more than RMB 30 million through centralized bidding on the Shanghai Stock Exchange starting from February 8, 2024[132]. Governance and Compliance - The company received a qualified audit opinion from the accounting firm Zhongchao Zhonghuan[5]. - The management emphasized the need for improved governance and internal control to address audit issues[3]. - The company has established a robust corporate governance structure, ensuring compliance with legal requirements and effective decision-making processes[85]. - The company has maintained independence from its controlling shareholder, ensuring that business operations and decision-making processes are separate and autonomous[86]. - The company emphasizes transparency in information disclosure, fulfilling obligations accurately and timely to protect the rights of shareholders, especially minority shareholders[88]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management to enhance their responsibility and work enthusiasm[88]. - The company has received multiple disciplinary actions from the Shanghai Stock Exchange on November 11, 2024, due to non-operational occupation of company funds and inaccurate financial disclosures[101]. - The company has implemented a review process for the remuneration of directors and senior management based on economic conditions and market salary levels[99]. Market and Industry Trends - The retail market for pharmaceuticals reached 501.9 billion yuan, with a slight increase of 0.8% year-on-year[38]. - The e-commerce channel for pharmaceuticals grew to 64.5 billion yuan, with a growth rate of 4.6%, increasing its market share to 12.9%[38]. - The clothing industry saw a total revenue of 1.27 trillion yuan, with a year-on-year growth of 2.76% among large enterprises[39]. - The company anticipates a recovery in domestic demand driven by government policies aimed at boosting consumption and investment[74]. - The company faces risks from intense brand competition, rapid changes in market demand, rising raw material prices, and increasing labor costs, which could impact operational strategies and performance[81][82]. Employee and Management Structure - The total number of employees in the parent company is 23, while the main subsidiaries employ 2,251, resulting in a total of 2,274 employees[110]. - The professional composition includes 1,426 production personnel, 664 sales personnel, and 132 technical personnel[111]. - The educational background shows that 986 employees have a college degree or higher, while 1,288 have a high school education or lower[111]. - The company has implemented a talent development strategy for 2024, focusing on diverse learning and development projects to enhance employee skills[113]. Future Outlook - Future outlook indicates a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[92]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the industry[92]. - A new product line is expected to launch in Q2 2024, anticipated to generate an additional 500 million in revenue[92].

（一）会议通知时间、方式 湖北美尔雅股份有限公司（以下简称"公司"）第十二届董事会第十七次会 议通知于2025年4月18日以传真、邮件、电话等形式发出。 （二）会议召开时间、地点、方式 本次会议于2025年4月28日在公司会议室采取现场结合通讯方式召开。 （三）董事出席会议情况及列席人员 本次会议应出席董事8人，实际出席8人，公司部分监事、高级管理人员列席 了会议。 证券代码：600107 证券简称：美尔雅 公告编号：2025016 湖北美尔雅股份有限公司 第十二届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （四）会议主持人 本次会议由董事长郑继平先生主持。 （五）会议召开的合规性 本次会议的召集、召开程序符合《中华人民共和国公司法》、《公司章程》 及有关法律、行政法规、部门规章、规范性文件的规定。 二、议案审议情况 本次会议议案采用书面记名投票表决方式进行，会议对以下议案进行了审议： （一）《2024年度总经理工作报告》 具体内容详见公司同日于上海证券交易所网站（htt ...

证券代码：600107 证券简称：美尔雅 公告编号：2025020 湖北美尔雅股份有限公司 关于 2024 年度利润分配及资本公积金转增股本方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： ●2024 年度不进行利润分配，不以公积金转增股本。 ●本次拟不进行利润分配的原因：公司考虑目前所处行业现状、运营发展 中的资金需求等因素，为保障公司业务持续稳定发展，增强公司抵御风险的能力， 公司提出 2024 年度不进行利润分配，不以公积金转增股本的方案。 ●尚需提交公司 2024 年年度股东大会审议。 一、利润分配方案内容 经中审众环会计师事务所(特殊普通合伙)审计，本公司 2024 年度实现归属 于母公司所有者的净利润-68,103,594.71 元，截止 2023 年 12 月 31 日，本公司 实际可供股东分配利润为-96,705,598.88 元。 为了抵御外部宏观环境压力，应对生产经营的成本上涨以及其他市场风险， 同时为补充发展所需流动资金，公司拟定 2024 年度不进行利润分配，也不进行 资本公积金转 ...